Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Market access, reimbursement and health-economic services

SubmarketREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Market access, reimbursement and health-economic services

Health-economic assessments, reimbursement dossiers, pricing analysis, payer-engagement strategy and commercial launch support for technologies.

Market size
$900M
$900M ($600M–$1.4B) · 2025 · Bottom-up
Growth
+9.0%
$1.9B by 2032
Attractiveness
60 /100
for B2B sellers
Evidence
Low confidence
3 sources · Bottom-up
Level
Submarket
Segmented by
Product or service
Buyers
Medical-device, diagnostic and digital-health vendors, pharmaceutical and biotechnology companies
Buying centre
Market access, health economics, medical affairs, commercial leadership, finance
Maturity
Emerging
Structure
Fragmented
Buying triggers
  • New device launch in a reimbursed market
  • HTA or national reimbursement submission deadline
  • Payer coverage decision requiring cost-effectiveness evidence
  • Price review or tender cycle
Pains
  • Unclear reimbursement pathway and evidence requirements
  • Slow and opaque payer decision processes
  • Internal teams lack health-economic modelling expertise
  • Risk of launch without coverage
Scores (1–5)
Pain intensity3
Purchasing power2
Reachability3
Growth4
Growth drivers
  • Payer pressure on device prices and cost-effectiveness evidence
  • HTA and reimbursement dossier requirements in EU HTA Regulation regimes
  • Shift from fee-for-service to value-based reimbursement
  • Launch sequencing across countries requiring local access strategy
Headwinds
  • Budget often discretionary and cut first in downturns
  • Payer-facing evidence increasingly produced in-house by large firms
  • Fragmented payer landscape raising cost of engagement
Trends
  • Health-economic dossiers becoming a standard part of launch packages
  • Real-world evidence linked to reimbursement outcomes
  • Pricing analytics and value-based contracting advisory
  • Integration of access services with regulatory and clinical evidence providers

Niches 5

Split by customer type.

Niche80/100

Cross-buyer launch support and health-economic evidence services

Medical-device, diagnostic, digital-health, pharmaceutical and biotechnology vendors buying integrated launch support, health-economic evidence development and cross-functional mar

—
Medical-device, diagnostic, digital-health, pharmaceutical and biotechnology vendors
not sizedOpen
Niche85/100

Medtech reimbursement dossiers and HTA submissions

Medical-device and diagnostic vendors buying evidence packages, reimbursement dossiers and payer-facing health-economic analyses to secure public reimbursement and coverage for dev

—
Medical-device and diagnostic manufacturers
not sizedOpen

How this was sized

$900M ($600M–$1.4B) · 2025 · Bottom-up

No source sizes this segment directly. Bottom-up: roughly 12,000-18,000 medtech, diagnostics and digital-health vendors in the US and EU with active products or in development [2] context; assume 25% engage external market-access support in a given year at USD 250k-500k average annual spend, giving USD 0.75-2.25B; midpoint USD 0.9B used. Growth assumed at 9% in line with the broader regulatory outsourcing CAGR range of 7.6-9.2% [5][9].

Alongside it in Clinical and regulatory support services

// Sell into Market access, reimbursement and health-economic services

AOS finds the biggest accounts in this submarket with a reason to talk now, maps their buying centre and prepares the outreach for your approval.